Linezolid Kabi (Linezolid)

Linezolid is an oxazolidinone antibacterial indicated for several serious infections.

• Skin and soft tissue infections: effective against Gram‑positive pathogens, including MRSA, reducing infection severity.
• Community‑acquired pneumonia: treats bacterial pneumonia caused by susceptible organisms, improving respiratory outcomes.
• Hospital‑acquired pneumonia: used for nosocomial pneumonia when alternative agents are unsuitable.
• MRSA infections: provides activity against methicillin‑resistant Staphylococcus aureus, facilitating clearance of skin, bloodstream or pulmonary disease.
• VRE infections: active against vancomycin‑resistant Enterococcus, aiding treatment of complicated infections.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for translation. This action blocks the early stage of peptide chain assembly, resulting in a bacteriostatic effect against most susceptible Gram‑positive organisms, including resistant strains such as MRSA and VRE. The binding is reversible and does not affect eukaryotic ribosomes, which contributes to its selective toxicity profile.

Linezolid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal upset often reported during therapy.
• Headache: transient headache occurring in some patients.
• Diarrhea: loose stools that may resolve without intervention.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Thrombocytopenia: significant reduction in platelet count requiring monitoring.
• Peripheral neuropathy: nerve damage presenting as tingling or numbness, potentially irreversible.
• Serum lactic acidosis: accumulation of lactate leading to metabolic acidosis, a rare but life‑threatening condition.
• Hypersensitivity reactions: severe allergic responses such as Stevens‑Johnson syndrome.

When prescribing Linezolid, clinicians should observe several precautionary measures to ensure patient safety.

• Renal impairment: dose adjustment may be required in patients with severe renal dysfunction.
• Hepatic dysfunction: monitor liver enzymes as linezolid can affect hepatic function.
• Hematologic monitoring: regular CBC checks are advised due to risk of thrombocytopenia and anemia.
• Concomitant serotonergic agents: avoid co‑administration because of risk of serotonin syndrome.
• Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited.
• Store at ambient temperature: keep vials in original packaging, protect from light and moisture, and store below 25 °C.

Linezolid interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: may precipitate serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): combined use can increase risk of hypertensive crisis.
• Rifampicin: potent enzyme inducer that can markedly reduce linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

• Tyramine‑containing foods and drugs: risk of hypertensive reactions due to MAO inhibition.
• Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring.
• Ethanol: potential for disulfiram‑like reaction; advise patient to limit alcohol intake.